About: Evaluation of glycoprotein E subunit and live attenuated varicella‐zoster virus vaccines formulated with a single‐strand RNA‐based adjuvant

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Evaluation of glycoprotein E subunit and live attenuated varicella‐zoster virus vaccines formulated with a single‐strand RNA‐based adjuvant Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Evaluation of glycoprotein E subunit and live attenuated varicella‐zoster virus vaccines formulated with a single‐strand RNA‐based adjuvant
Creator	Lee, Eun Lee, Hyun Nam, Jae-Hwan Park, Hyo-Jung Lee, Su Kim, \| Correspondence, Jae-Hwan Jung, \| Li, Hae Nam,
Source	Medline; PMC
abstract	INTRODUCTION: Varicella‐zoster virus (VZV), a human alphaherpesvirus 3, elicits both chickenpox and shingles and/or postherpetic neuralgia. A live attenuated vaccine (LAV) and glycoprotein E (gE) subunit vaccine were developed to prevent VZV‐induced diseases. We recently reported that single‐strand RNA (ssRNA) based on the intergenic region of the internal ribosome entry site of cricket paralysis virus (CrPV) is an effective adjuvant for protein‐based and virus‐like particle‐based vaccines. Here, Chinese hamster ovary expression system and an LAV from Oka/SK strains. METHODS: We appraised the adjuvant effect of the same CrPV ssRNA encoding the gE gene formulated in the two vaccines using VZV‐primed C57BL/6 mice and guinea pigs. Humoral immunity and cell‐mediated immunity were assessed by enzyme‐linked immunosorbent assay (ELISA) and ELISPOT in gE subunit vaccine and by ELISA and fluorescent antibody to membrane antigen in LAV. RESULTS: The gE subunit vaccine‐induced gE‐specific antibodies and CD4(+) T‐cell responses (indicated by interferon‐γ [IFN‐γ] and interleukin‐2 secretion) in the ssRNA‐based adjuvant containing the VZV gE gene. Therefore, an ssRNA adjuvant combined with gE antigen can trigger the innate immune response and induce an adaptive immune response to ultimately activate humoral and cell‐mediated responses. VZV LAV could also induce VZV‐specific antibodies and IFN‐γ stimulated by LAV, whereas the effect of ssRNA as a vaccine adjuvant could not be confirmed. However, the ssRNA adjuvant increased VZV‐specific neutralizing antibody response. CONCLUSIONS: Taken together, these results highlight that the gE subunit vaccine and LAV developed in this study can be functional VZV vaccines, and ssRNAs appear to function better as adjuvants in a subunit vaccine than in an LAV.
has issue date	2020-03-13(xsd:dateTime)
bibo:doi	10.1002/iid3.297
bibo:pmid	32167678
has license	cc-by
sha1sum (hex)	8283f147574b1e6ea7ce216707b66a6b3e23fc94
schema:url	https://doi.org/10.1002/iid3.297
resource representing a document's title	Evaluation of glycoprotein E subunit and live attenuated varicella‐zoster virus vaccines formulated with a single‐strand RNA‐based adjuvant
has PubMed Central identifier	PMC7212201
has PubMed identifier	32167678
schema:publication	Immun Inflamm Dis
resource representing a document's body	covid:8283f147574b1e6ea7ce216707b66a6b3e23fc94#body_text
is schema:about of	named entity 'live attenuated' named entity 'diseases' named entity 'intergenic region' named entity 'subunit' named entity 'RNA-based' named entity 'ELISPOT' named entity 'RESULTS' named entity 'USING' covid:arg/8283f147574b1e6ea7ce216707b66a6b3e23fc94 named entity 'VZV' named entity 'C57BL/6' named entity 'postherpetic neuralgia' named entity 'developed' named entity 'internal ribosome entry site' named entity 'subunit vaccine' named entity 'shingles' named entity 'mice' named entity 'Chinese hamster ovary' named entity 'VZV' named entity 'RNA' named entity 'vaccines' named entity 'cricket paralysis virus' named entity 'internal ribosome entry site' named entity 'C57BL/6' named entity 'gene' named entity 'glycoprotein' named entity 'glycoprotein' named entity 'substrate' named entity 'Bio-Rad Laboratories' named entity 'fetal bovine serum' named entity 'antigen' named entity 'varicella' named entity 'CrPV' named entity 'potency' named entity 'gene' named entity 'antibody' named entity 'liposome' named entity 'immune markers' named entity 'IgG' named entity 'subunit vaccine' named entity 'IgG2' named entity '450 nm' named entity 'CD4 +' named entity 'VZV' named entity 'glycoproteins' named entity 'single cells' named entity 'innate immune responses' named entity 'Zostavax' named entity 'VZV' named entity 'ssRNA' named entity 'assay' named entity 'cytokines' named entity 'positive control' named entity 'aging process' named entity 'humoral' named entity 'enzyme-linked immunosorbent assay' named entity 'IL-2' named entity 'adjuvant' named entity 'ssRNA' named entity 'amino acids' named entity 'ssRNA' named entity 'primer' named entity 'A549' named entity 'lysed' named entity 'Th1 cells' named entity 'ssRNA' named entity 'IL-2' named entity 'subcutaneously injected' named entity 'VZV' named entity 'IL-2' named entity 'RNA' named entity 'subunit vaccine'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software